Benzinga | Jul 21, 2020 07:11AM EDT

First Commercial Product Using Antares Pharma's Multi-Dose Pen Platform Launches in Europe

EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") ("the Company"), a pharmaceutical technology company, announced the first commercialization of the Company's multi-dose pen platform launched in Europe. Antares development partner Teva, launched Teriparatide Injection ("teriparatide"), the generic version of Eli Lilly's brand product Forsteo(r) featuring the Antares multi-dose pen platform in Austria, Croatia, Hungary, The Netherlands, Portugal, Sweden, Switzerland and The United Kingdom and is expected to launch in other European countries later this year.

Teriparatide injection is a drug-device combination product indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men, and in postmenopausal women and in men at increased risk of fracture.

"The European launch of this product represents the achievement of another milestone in our development collaboration with Teva. This is the third successful approval and launch of a drug device combination product which follows the previous launches of the generic epinephrine auto injector and the generic sumatriptan auto injector," said Robert F. Apple, President and Chief Executive Officer of Antares Pharma.

Antares previously entered into an exclusive Development, License and Supply Agreement with Teva Pharmaceutical Industries, Ltd. ("Teva"), a global leader in generic and specialty medicines, for a teriparatide injection product to be marketed globally, once approved by the respective regulatory authorities. Antares is responsible for the manufacturing and supply of the multi-dose pen utilized in Teva's generic teriparatide product. The scope of the teriparatide license and supply agreement with Teva is worldwide.